Skip to main content
Equibles

K2 PRINCIPAL FUND, L.P.

Position in ABVX — Abivax S.A.

CIK 1461790 TORONTO, A6
Back to ABVX Full portfolio

Position in ABVX

as of Jun 30, 2026 · filed Aug 7, 2026
Position Value
$3,251,943
-$2,732,117 QoQ
Shares Held
24,403
-54.6% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.86%
of 13F equity value
Holder Rank
#128
of 302 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ABVX Over Time

Shares Held

Position Value (USD)

Derivatives in ABVX

reported options exposure · as of Jun 30, 2026
CallValue
$11,340,426
CallShares
85,100
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

K2 PRINCIPAL FUND, L.P. holds $13,545,573 across 5 Biotechnology names. ABVX ranks #3 (24.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 QURE
uniQure N.V.
 78,601 $3,620,362
2 NKTR
Nektar Therapeutics
 50,465 $3,522,961
3 ABVX
Abivax S.A.
This page 		24,403 $3,251,943
4 SPRY
ARS Pharmaceuticals, Inc.
 375,132 $3,004,807
5 TENX
Tenax Therapeutics, Inc.
 10,000 $145,500

All Filings in ABVX

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,251,943 24,403
2026-06-30 $11,340,426 85,100
2026-03-31 $1,113,500 10,000
2026-03-31 $5,984,060 53,741
2025-12-31 $3,034,237 22,500
2025-12-31 $1,348,550 10,000